Recursion Pharmaceuticals is a primary investment opportunity for its disruptive approach to drug discovery, using a biological data engine with automation and AI to identify drug candidates faster and more efficiently.
Source Post
The 1% Are Quietly Buying These 2 AI Healthcare Stocks
Apr 15, 2026
The creator highlights two AI-driven healthcare companies, Tempus AI (TM) and Recursion Pharmaceuticals (RXRX), as potential long-term investments. Tempus AI is building a massive clinical and genomic data set to improve disease detection and treatment, while Recursion Pharmaceuticals is using automation and AI to revolutionize drug discovery. Both companies are leveraging AI to create moats and address inefficiencies in the healthcare industry.
Linked Mentions
Tickers discussed in this post
Tempus AI is a primary investment opportunity due to its massive, continuously growing data set connecting clinical outcomes with genomic data, creating a strong feedback loop and moat in AI-driven precision medicine.